Cite
31P Integrated safety analysis of anti-programmed cell death-1 (PD-1) antibody penpulimab in advanced solid tumour or lymphoma.
MLA
Xu, N., et al. “31P Integrated Safety Analysis of Anti-Programmed Cell Death-1 (PD-1) Antibody Penpulimab in Advanced Solid Tumour or Lymphoma.” Annals of Oncology, vol. 31, Dec. 2020, pp. S1428–29. EBSCOhost, https://doi.org/10.1016/j.annonc.2020.10.518.
APA
Xu, N., Han, B., Jiao, S., Hu, C., Mislang, A., Coward, J., Cooper, A., Underhill, C., Xia, Y., Xia, D., Jin, X., Wang, Z. M., & Li, B. (2020). 31P Integrated safety analysis of anti-programmed cell death-1 (PD-1) antibody penpulimab in advanced solid tumour or lymphoma. Annals of Oncology, 31, S1428–S1429. https://doi.org/10.1016/j.annonc.2020.10.518
Chicago
Xu, N., B. Han, S. Jiao, C. Hu, A. Mislang, J. Coward, A. Cooper, et al. 2020. “31P Integrated Safety Analysis of Anti-Programmed Cell Death-1 (PD-1) Antibody Penpulimab in Advanced Solid Tumour or Lymphoma.” Annals of Oncology 31 (December): S1428–29. doi:10.1016/j.annonc.2020.10.518.